The Center for Medicare and Medicaid Innovation - toward value based care

9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...

Read more →

Supporting innovation in Medicaid policy - interventions to increase adoption of RCTs

7 May 2022 - Randomised, controlled trials remain underutilised within the Medicaid program, even though state Medicaid programs regularly implement new ...

Read more →

Risks to the 340B drug pricing program related to manufacturer restrictions on drug availability

15 April 2022 - On 21 March 2022, Johnson & Johnson became the 16th pharmaceutical manufacturer to restrict the delivery of ...

Read more →

Recent trends in Medicaid spending and use of drugs with US Food and Drug Administration accelerated approval

8 October 2021 - In this cross-sectional study of 216 drugs granted accelerated approval from 1992 through 2020, relative to all ...

Read more →

Health equity and Medicaid transformation — operationalising President Biden’s agenda

19 June 2021 - President Biden has made reforms intended to “protect and strengthen Medicaid” a centrepiece of his health policy ...

Read more →

Medicare and Medicaid to cover early COVID-19 vaccine

26 October 2020 - The new regulations would allow beneficiaries to receive a vaccine under “emergency authorisation” at no cost. ...

Read more →

CMS proposes changes to Medicaid best price rule: a potential boost to value-based contracting

9 August 2020 - For well over a decade policymakers have declared the healthcare system is moving towards value-based pricing ...

Read more →

Trump Administration proposes Medicaid reforms to encourage innovative contracting models

22 June 2020 - On Wednesday, June 17, the Centers for Medicare and Medicaid Services proposed a series of reforms ...

Read more →

Estimating the cost of delayed generic drug entry to Medicaid

1 June 2020 - Delays in market entry of generic drugs are common.  ...

Read more →

Alternative drug purchasing arrangements do not justify raising the prices Medicaid pays for brand drugs

3 April 2020 - As the prescription drug pipeline fills with very high-cost gene therapies and specialty drugs, affordability and access ...

Read more →

Trump’s Medicaid changes offer states new powers to lower drug costs — with a catch

31 January 2020 - The Trump administration on Thursday unveiled a powerful new tool for states to rein in prescription ...

Read more →

Most state Medicaid programs continue to restrict access to hepatitis C medicines

16 October 2019 - Despite guidance from the federal government, most state Medicaid programs continue to deny hepatitis C treatments ...

Read more →

CMS approves Louisiana State Plan Amendment for supplemental rebate agreements using a modified subscription model for hepatitis C therapies in Medicaid

26 June 2019 - State Plan Amendment permits Louisiana to negotiate supplemental drug rebates to assist the state in controlling expenditures ...

Read more →

Extending VBP models into Medicaid drug purchasing: challenges and opportunities

22 May 2019 - Over the past decade, both public and private payers have increasingly sought to develop payment policies that ...

Read more →

Pazdur on pandemonium: calls for collaboration, competition on PD-1 drugs

8 April 2019 - Pazdur chastises PD-1/PD-L1 pharmas for losing sight of patients. ...

Read more →